Jenny Kim-Kosowski
Piscataway, NJNPI 1063821114
Payments from drug & device makers
Across 233 payments — averaging $14.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$659
- AbbVie$587
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$440
- Tris Pharma Inc$246
- Otsuka America Pharmaceutical, Inc.$207
- Corium, LLC$186
- plus $1K from 13 others
What the payments were for
- Food & beverage$3,333100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 41 | $659 |
| AbbVie(2 entities) | 55 | $587 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $440 |
| Tris Pharma Inc | 16 | $246 |
| Otsuka America Pharmaceutical, Inc. | 13 | $207 |
| Corium, LLC | 16 | $186 |
| Lundbeck LLC | 10 | $173 |
| Neos Therapeutics, LP | 11 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $140 |
| Ironshore Pharmaceuticals Inc. | 8 | $123 |
| Johnson & Johnson | 7 | $113 |
| Axsome Therapeutics, Inc. | 4 | $62 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| Alkermes, Inc. | 3 | $51 |
| Tempus AI, Inc | 2 | $32 |
| Collegium Pharmaceutical, Inc. | 2 | $31 |
| Shire North American Group Inc | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$125
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonazepam | 11 | $288 |
| Alprazolam | 11 | $176 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $104 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.